4EVT (4EVT)

Overview

Evotec SE, headquartered in Hamburg, Germany, is a leading drug discovery and development partner for the pharmaceutical and biotechnology industry globally. Initially known as Evotec AG, the company underwent a name change to Evotec SE in April 2019. Founded in 1993, Evotec has established itself as a vital player in the field, focusing on advancing pharmaceutical products across a broad range of therapeutic areas. The company boasts an extensive portfolio of collaboration agreements with top industry names, including Bayer, Lilly, Almirall, and Pfizer Inc., among others. Additionally, Evotec has strategic partnerships, notably with Dewpoint Therapeutics aimed at advancing oncology pipeline programs, and a licensing agreement with Glycotope GmbH for the development of next-generation immune cell engaging bispecifics targeting various indications, including solid tumors.

Products and Services

Evotec SE's offerings encompass a wide array of drug discovery and development services across multiple therapeutic areas. Among these are:

• Diabetes and Complications: Evotec focuses on identifying novel treatments for diabetes and its associated complications, addressing a significant unmet medical need.
• Fibrosis: The company is engaged in the discovery and development of therapies aimed at treating fibrotic diseases, conditions characterized by excessive tissue scarring.
• Infectious Diseases: Evotec works on the development of antibiotics and antiviral drugs to combat various infectious diseases, an area of increasing importance given global health challenges.
• CNS Diseases: The company is dedicated to finding solutions for central nervous system (CNS) disorders, striving to improve the quality of life for patients suffering from these conditions.
• Oncology: Evotec is actively developing cancer treatments, focusing on both solid tumors and hematological cancers, to offer novel therapeutic options.
• Pain and Inflammation: With a commitment to addressing the root causes of pain and inflammation, Evotec is pursuing advancements in this therapeutic area to provide relief to patients.
• Immunology: The company's efforts in immunology are centered on developing treatments that modulate the immune system to fight diseases more effectively.
• Rare Diseases: Evotec is dedicated to addressing the challenges of rare diseases, offering hope through the development of targeted therapies.
• Respiratory Diseases: The company extends its expertise to the respiratory domain, aiming to enhance treatment options for diseases affecting the respiratory system.
• Women's Health: A focus area for Evotec includes women's health, where the company seeks to improve healthcare outcomes for conditions uniquely affecting women.